| 证券代码 | SRRA.O |
| 证券名称 | Sierra Oncology Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-07-16 |
| 首发价格(元) | 17 USD |
| 首发数量(股) | 8100000 |
| 首发募资额(元) | 137,700,000.00 USD |
| 首发主承销商 | BofA Merrill Lynch,Jefferies LLC |
| 货币单位 | USD |
| 公司名称 | Sierra Oncology, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 2150 - 885 West Georgia Street, Vancouver, British Columbia, Canada |
| 成立日期 | 2003-05 |
| 董事会主席 | Robert Pelzer |
| 公司属地 | United States 美国 |
| 公司网址 | www.sierraoncology.com |
| 电话 | +1 (604) 558-6536 |
| 传真 | - |
| 公司简介 | Sierra Oncology, Inc. is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNA interference (DNAi) technology platform. Its vision is to be the leader in developing and commercializing a portfolio of DNAi-based therapies to deliver extraordinary therapeutic outcomes that dramatically change patients’ lives. The core of its scientific expertise is its understanding of DNAi oligonucleotides, which are rationally designed DNA sequences that modulate the transcription of oncogenes known to be involved in cancer cell survival and proliferation. Its lead DNAi product candidate, PNT2258, targets BCL2, a widely overexpressed oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer. In a recent single-agent Phase 2 trial of 13 patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), PNT2258 demonstrated evidence of anti-tumor activity, with 11 patients achieving a complete response (CR), partial response (PR) or stable disease (SD). Furthermore, all four of the diffuse large B-cell lymphoma (DLBCL) patients treated in this trial experienced a clinical response, including three CRs and one PR, with reported durations on study in the range of nine to more than 20 months. Although not statistically powered for a formal efficacy analysis, the company believe the preliminary evidence of efficacy observed in this trial, coupled with safety and tolerability data collected to date, suggest that PNT2258 has the potential to change treatment paradigms across a wide range of oncology indications. Accordingly, the company plan to pursue a broad registration-oriented clinical development program, initially in hematologic malignancies, that the company anticipate will provide the foundation of a global registration strategy for PNT2258. |